These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1003 related articles for article (PubMed ID: 32303618)
1. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149 [TBL] [Abstract][Full Text] [Related]
3. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527 [TBL] [Abstract][Full Text] [Related]
4. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612 [TBL] [Abstract][Full Text] [Related]
5. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925 [TBL] [Abstract][Full Text] [Related]
6. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714 [TBL] [Abstract][Full Text] [Related]
7. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930 [TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
9. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model. Burrack AL; Rollins MR; Spartz EJ; Mesojednik TD; Schmiechen ZC; Raynor JF; Wang IX; Kedl RM; Stromnes IM J Immunol; 2021 Mar; 206(6):1372-1384. PubMed ID: 33558374 [TBL] [Abstract][Full Text] [Related]
10. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386 [TBL] [Abstract][Full Text] [Related]
13. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777 [TBL] [Abstract][Full Text] [Related]
15. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149 [TBL] [Abstract][Full Text] [Related]
16. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020 [TBL] [Abstract][Full Text] [Related]
17. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929 [TBL] [Abstract][Full Text] [Related]